Labcorp lays out priorities and progress in Corporate Responsibility Report

BURLINGTON, N.C. --(BUSINESS WIRE)--Mar. 25, 2021-- Labcorp (NYSE: LH), a leading global life sciences company, today issued its 2019-2020 Corporate Responsibility Report: Making a Difference When It Counts. The report includes the ways in which Labcorp carries out its mission of improving health and improving lives, and charts its progress on priorities including the company’s environmental, health, and safety performance, as well as its community partnerships and its commitments to advancing diversity and inclusion.

Labcorp business update

BURLINGTON, N.C. --(BUSINESS WIRE)--Mar. 23, 2021-- Labcorp (NYSE: LH), a leading life sciences company, today issued the following statement: Labcorp continues to make progress executing our strategy and capitalizing on the power of our diagnostic and drug development businesses.

Dr. Marcia Eisenberg, Chief Scientific Officer of Labcorp Diagnostics, named a Healthcare Businesswoman’s Association Luminary

BURLINGTON, N.C. --(BUSINESS WIRE)--Mar. 23, 2021-- Labcorp (NYSE: LH), a leading global life sciences company, today announced that Marcia Eisenberg , Ph.D., chief scientific officer of Labcorp Diagnostics , was recognized by the Healthcare Businesswomen’s Association (HBA) as a 2021 Luminary.

Labcorp scheduled to speak at KeyBanc Capital Markets' Life Sciences and MedTech Investor Forum

BURLINGTON, N.C. --(BUSINESS WIRE)--Mar. 19, 2021-- Labcorp (NYSE: LH), a leading global life sciences company, today announced that members of the executive management team will participate in a virtual fireside chat at KeyBanc Capital Markets'   Life Sciences and MedTech Investor Forum on Wednesday, March 24 at 2:00 p.m. ET.

PathAI and Labcorp broaden strategic collaboration to accelerate use of AI-powered pathology

BOSTON and BURLINGTON, N.C. – March 8, 2021 – PathAI, a global provider of artificial intelligence-powered (AI-powered) technology for use in pathology research, and Labcorp (NYSE: LH), a leading global life sciences company, today announced the broadening of their strategic partnership in the field of AI-powered pathology. The collaboration builds on Labcorp’s past investment in PathAI and the companies’ collaboration on a series of projects, including the deployment of PathAI algorithms in clinical trials managed by Labcorp Drug Development.